Display options
Cite
Monro A. Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses. J Pharmacokinet Biopharm. 1994;22(1):41-57doi: 10.1007/BF02353409.
Monro, A. (1994). Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses. Journal of pharmacokinetics and biopharmaceutics, 22(1), 41-57. https://doi.org/10.1007/BF02353409
Monro, A. "Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses." Journal of pharmacokinetics and biopharmaceutics vol. 22,1 (1994): 41-57. doi: https://doi.org/10.1007/BF02353409
Monro A. Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses. J Pharmacokinet Biopharm. 1994 Feb;22(1):41-57. doi: 10.1007/BF02353409. PMID: 8027948.
Copy Download .nbib Format: NLM
Share it on

J Pharmacokinet Biopharm. 1994 Feb;22(1):41-57. doi: 10.1007/BF02353409.

Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.

Journal of pharmacokinetics and biopharmaceutics

A Monro

Affiliations

  1. Pfizer Central Research, Groton, Connecticut 06340.

PMID: 8027948 DOI: 10.1007/BF02353409

Abstract

Toxicokinetics describes the concentration and time course of a xenobiotic in the circulation under the conditions of a toxicology study. However, the fundamental challenge to the toxicologist, of extrapolating the findings in animals to a risk assessment in humans, requires knowledge and understanding of both the pharmacokinetics and pharmacodynamic responses in each species. This paper exemplifies situations where measurement of plasma concentrations may provide information useful in the design and interpretation of the toxicity observed in a given species; it also illustrates how intrinsic interspecies differences in pharmacodynamic response limit the extrapolation of toxicity data across species. The special case of the multistage cumulative phenomenon of carcinogenicity, with the implications of daily dose, duration of dosing, and species differences in response, is also discussed.

References

  1. Environ Health Perspect. 1991 Aug;94:195-218 - PubMed
  2. Clin Pharmacokinet. 1978 Mar-Apr;3(2):144-54 - PubMed
  3. Brain Res. 1987 Sep 1;419(1-2):65-75 - PubMed
  4. Science. 1990 Aug 31;249(4972):970-1 - PubMed
  5. Toxicol Appl Pharmacol. 1991 Mar 1;107(3):562-7 - PubMed
  6. Cancer Chemother Pharmacol. 1987;20(4):305-10 - PubMed
  7. Pharmacol Rev. 1988 Mar;40(1):1-47 - PubMed
  8. Annu Rev Pharmacol Toxicol. 1991;31:621-52 - PubMed
  9. Environ Health Perspect. 1989 May;81:211-9 - PubMed
  10. Xenobiotica. 1990 Nov;20(11):1187-99 - PubMed
  11. FEBS Lett. 1992 Aug 3;307(3):324-8 - PubMed
  12. Regul Toxicol Pharmacol. 1991 Oct;14(2):118-46 - PubMed
  13. Regul Toxicol Pharmacol. 1992 Apr;15(2 Pt 1):180-221 - PubMed
  14. DNA Cell Biol. 1991 Jan-Feb;10(1):1-14 - PubMed
  15. Annu Rev Pharmacol Toxicol. 1991;31:101-28 - PubMed
  16. Biochem Soc Trans. 1992 Feb;20(1):118-21 - PubMed
  17. Fundam Appl Toxicol. 1992 Aug;19(2):207-13 - PubMed
  18. Drug Metab Dispos. 1990 Jul-Aug;18(4):467-70 - PubMed
  19. Br J Cancer. 1975 Oct;32(4):411-26 - PubMed
  20. Environ Health Perspect. 1991 Dec;96:5-9 - PubMed
  21. Cancer Res. 1991 Dec 15;51(24):6493-505 - PubMed
  22. Am J Physiol. 1983 Dec;245(6):H957-61 - PubMed
  23. Regul Toxicol Pharmacol. 1993 Aug;18(1):115-35 - PubMed
  24. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7772-6 - PubMed
  25. Brain Res. 1986 Jun 18;376(1):85-96 - PubMed
  26. Toxicol Lett. 1988 Oct;43(1-3):189-200 - PubMed
  27. Eur J Pharmacol. 1991 Jul 9;199(3):291-301 - PubMed
  28. Toxicol Appl Pharmacol. 1992 Feb;112(2):171-81 - PubMed
  29. Xenobiotica. 1992 Jul;22(7):743-55 - PubMed
  30. J Antimicrob Chemother. 1990 Jan;25 Suppl A:49-60 - PubMed
  31. Annu Rev Pharmacol Toxicol. 1992;32:271-302 - PubMed
  32. Adverse Drug React Toxicol Rev. 1993 Spring;12(1):5-34 - PubMed
  33. J Natl Cancer Inst. 1981 Jun;66(6):1037-52 - PubMed

Substances

MeSH terms

Publication Types